Rilotumumab, formerly known as AMG 102, is a antibody mainly utilized as a valuable research means to probe the pathways driving tumor growth . The experimental selectively targets the IGF-1R , a critical driver in several cancer types . Investigators utilize AMG 102 to isolate the function of IG… Read More

A agent galcanezumab, initially developed as LY2951742, represents a critical advance in migraine treatment. Its chemical identity is that of the humanized monoclonal protein, specifically targeting CGRP receptor. The sophisticated molecule is heavy and minor chains, linked by disulfide connectio… Read More

Emicizumab, designated bROmI is representing a significant advancement in treating bleeding disease . This innovative factor functions as a prothrombin molecule, mimicking factor VIII, a element often deficient in patients with hemophilia A . Unlike existing factor treatments, emicizumab delivers… Read More

The introduction of troglitazone, a potent antidiabetic agent, marked a important chapter in the treatment of type 2 diabetes. However, its withdrawal from the market due to serious hepatotoxicity spurred considerable investigation into related thiazolidinediones. Following pioglitazone and rosig… Read More